Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers
详细信息 查看全文
- 作者：Gabriele Valentini (1)
Antonella Marcoccia (2)
Giovanna Cuomo (1)
Serena Vettori (1)
Michele Iudici (1)
Francesco Bondanini (3)
Carlo Santoriello (4)
Aldo Ciani (5)
Domenico Cozzolino (6)
Giovanni Maria De Matteis (7)
Salvatore Cappabianca (8)
Filiberto Vitelli (9)
Alberto Spanò (3) - 关键词：Raynaud's phenomenon ; early systemic sclerosis ; systemic sclerosis marker autoantibodies ; nailfold videocapillaroscopy ; preclinical organ involvement ; puffy fingerscirculating activation markers ; carboxyterminal propeptide of collagen I ; soluble E ; selectin ; soluble IL ; 2 receptor alpha
- 刊名：Arthritis Research & Therapy
- 出版年：2013
- 出版时间：June 2013
- 年：2013
- 卷：15
- 期：3
- 全文大小：454 KB
- 参考文献：1. LeRoy EC, Medsger TA Jr: Criteria for the classification of early systemic sclerosis. / J Rheumatol 2001, 28:1573-576.
2. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Goulet JR, Rich E, Grodzicky T, Raymond Y, Senécal JL: Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis. A twenty-year prospective study of 586 patients with validation of proposed criteria for early systemic sclerosis. / Arthritis Rheum 2008, 58:3902-912. CrossRef
3. Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A, Cozzolino D, Del Genio G, Santoriello C: Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. / Rheumatology (Oxford) 2011, 50:317-23. CrossRef
4. Valentini G, Vettori S, Cuomo G, Iudici M, D'Abrosca V, Capocotta D, Del Genio G, Santoriello C, Cozzolino D: Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement. / Arthritis Res Ther 2012, 14:R188. CrossRef
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for classification of systemic sclerosis (scleroderma). / Arthritis Rheum 1980, 23:581-90. CrossRef
6. LeRoy EC, Medsger TA Jr: Raynaud's phenomenon: a proposal for classification. / Clin Exp Rheumatol 1992, 10:485-88.
7. Sebastiani M, Manfredi A, Vukatana G, Moscatelli S, Riato L, Bocci M, Iudici M, Principato A, Mazzuca S, Del Medico P, De Angelis R, D'Amico R, Vicini R, Colaci M, Ferri C: Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. / Ann Rheum Dis 2012, 71:67-0. CrossRef
8. Maricq HR: Widefield capillary microscopy: technique and rating scale for abnormalities seen in scleroderma and related disorders. / Arthritis Rheum 1981, 24:1159-165. CrossRef
9. Scussel-Lonzetti L, Joyal F, Raynauld J-P, Roussin A, Rich E, Goulet JR, Raymond Y, Senécal JL: Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. / Medicine (Baltimore) 2002, 81:154-67. CrossRef
10. Caramaschi P, Canestrini S, Martinelli N, Volpe A, Pieropan S, Ferrari M, Bambara LM, Carletto A, Biasi D: Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. / Rheumatology 2007, 46:1566-569. CrossRef
11. Nishimura RA, Miller FA Jr, Callahan MJ, Benassi RC, Seward JB, Tajik AS: Doppler echocardiography: theory, instrumentation, technique and application. / Mayo Clin Proc 1985, 60:321-43. CrossRef
12. Maione S, Cuomo G, Giunta A, Tanturri de Horatio L, La Montagna G, Manguso F, Alagia I, Valentini G: Echocardiographic alterations in systemic sclerosis. A longitudinal study. / Semin Arthritis Rheum 2005, 34:721-27. CrossRef
13. Ogilvie CM, Forster RE, Blakemore WS, Morton JW: A standardized breath holding technique for clinical measurement of the diffusing capacity of the lung for carbon monoxide. / J Clin Invest 1957, 36:1-7. CrossRef
14. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA: Pulmonary involvement in systemic sclerosis (scleroderma). / Arthritis Rheum 1985, 28:759-67. CrossRef
15. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP, Toews G: Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. / Am J Roentgenol 1997, 169:977-83. CrossRef
16. Walker UA, Tyndall A, Czirják L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Matucci-Cerinic M, EUSTAR co-authors: Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. / Ann Rheum Dis 2009, 68:856-62. CrossRef
17. Wells AU, Steen V, Valentini G: Pulmonary complications: one of the most challenging complications of systemic sclerosis. / Rheumatology (Oxford) 2009,48(Suppl 3):40-4.
18. Scheja A, Wildt M, Wollheim FA, Akesson A, Saxne T: Circulating collagen metabolities in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. / Rheumatology 2000, 39:1110-113. CrossRef
19. Allanore Y, Borderie D, Lemaréchal H, Cherrau B, Ekindjian OG, Kahan A: Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and and pulmonary involvement in systemic sclerosis. / J Rheumatol 2003, 30:68-3.
20. LeRoy EC, Maricq HR, Kahaleh MB: Undifferentiated connective tissue syndromes. / Arthritis Rheum 1980, 23:341-43. CrossRef
21. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K: Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. / Br J Rheumatol 1998, 37:1188-192. CrossRef
22. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K Jr: Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. / Arthritis Rheum 1990, 33:375-80. CrossRef
23. Englert H, Champion D, Wu JC, Giallussi J, McGrath M, Manolios N: Antitopoisomerase antibody positivity predates nailfold capillaroscopy abnormalities in scleroderma. Postulated classification of 'prescleroderma'. / Intern Med J 2011, 41:197-99. CrossRef
24. Moinzadeh Pia, Nihtyanova SI, Howell K, Ong VH, Denton CP: Impact of hallmark autoantibody reactivity on early diagnosis of scleroderma. / Clin Rev Allergy Immunol 2012, in press.
25. Matucci-Cerinic M, Allanore Y, Czirják L, Tyndall A, Müller-Ladner U, Denton C, Valentini G, Distler O, Fligelstone K, Tyrrel-Kennedy A, Farge D, Kowal-Bielecka O, van den Hoogen F, Cutolo M, Sampaio-Barros PD, Nash P, Takehara K, Furst DE: The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. / Ann Rheum Dis 2009, 68:1377-380. CrossRef
26. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L, Müller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M, EUSTAR Group: Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. / Ann Rheum Dis 2011, 70:476-81. CrossRef
27. Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, Czirják L, Denton CP, Distler O, Furst DE, Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger TA Jr, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk MC, Walker U, Chung L, Clements PJ, Collier DH, Csuka ME, Jimenez S, Merkel PA, Seibold JR, / et al.: Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. / Arthritis Care Res 2012, 64:351-57. CrossRef
28. Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger TA Jr, Peschken CA, Carreira PE, Riemekasten G, Tyndall A, Matucci-Cerinic M, Pope JE: Validation of potential classification criteria for systemic sclerosis. / Arthritis Care Res 2012, 64:358-67. CrossRef - 作者单位：Gabriele Valentini (1)
Antonella Marcoccia (2)
Giovanna Cuomo (1)
Serena Vettori (1)
Michele Iudici (1)
Francesco Bondanini (3)
Carlo Santoriello (4)
Aldo Ciani (5)
Domenico Cozzolino (6)
Giovanni Maria De Matteis (7)
Salvatore Cappabianca (8)
Filiberto Vitelli (9)
Alberto Spanò (3)
1. Rheumatology Unit, Second University of Naples, via Pansini 5, 80131, Naples, Italy
2. Angiology Unit, Sandro Pertini Hospital, via dei Monti Tiburtini 385, 00157, Rome, Italy
3. Clinical Biochemistry Service, Sandro Pertini Hospital, via dei Monti Tiburtini 385, 00157, Rome, Italy
4. Respiratory Physiopathology Unit, ASL-SA1, via Santoriello 2, Cava dei Tirreni, (SA), Italy
5. Pneumology Unit, Sandro Pertini Hospital, via dei Monti Tiburtini 385, 00157, Rome, Italy
6. Internal Medicine Unit, Second University of Naples, via Pansini 5, 80131, Naples, Italy
7. Cardiology Unit, Sandro Pertini Hospital, via dei Monti Tiburtini 385, 00157, Rome, Italy
8. Radiology, Radiotherapy and Nuclear Medicine Unit, Second University of Naples, Piazza Miraglia 5, 80131, Naples, Italy
9. Radiology Unit, Sandro Pertini Hospital, via dei Monti Tiburtini 385, 00157, Rome, Italy - ISSN：1478-6354
文摘
Introduction Early systemic sclerosis (SSc) is characterized by Raynaud's phenomenon together with scleroderma marker autoantibodies and/or a scleroderma pattern at capillaroscopy and no other distinctive feature of SSc. Patients presenting with marker autoantibodies plus a capillaroscopic scleroderma pattern seem to evolve into definite SSc more frequently than patients with either feature. Whether early SSc patients with only marker autoantibodies or capillaroscopic positivity differ in any aspect at presentation is unclear. Methods Seventy-one consecutive early SSc patients were investigated for preclinical cardiopulmonary alterations. Out of these, 44 patients and 25 controls affected by osteoarthritis or primary fibromyalgia syndrome were also investigated for serum markers of fibroblast (carboxyterminal propeptide of collagen I), endothelial (soluble E-selectin) and T-cell (soluble IL-2 receptor alpha) activation. Results Thirty-two of the 71 patients (45.1%) had both a marker autoantibody and a capillaroscopic scleroderma pattern (subset 1), 16 patients (22.5%) had only a marker autoantibody (subset 2), and 23 patients (32.4%) had only a capillaroscopic scleroderma pattern (subset 3). Patients with marker autoantibodies (n = 48, 67.6%) had a higher prevalence of impaired diffusing lung capacity for carbon monoxide (P = 0.0217) and increased serum levels of carboxyterminal propeptide of collagen I (P = 0.0037), regardless of capillaroscopic alterations. Patients with a capillaroscopic scleroderma pattern (n = 55, 77.5%) had a higher prevalence of puffy fingers (P = 0.0001) and increased serum levels of soluble E-selectin (P = 0.0003) regardless of marker autoantibodies. Conclusion These results suggest that the autoantibody and microvascular patterns in early SSc may each be related to different clinical-preclinical features and circulating activation markers at presentation. Longitudinal studies are warranted to investigate whether these subsets undergo a different disease course over time.